Advanced search
Publication Cover
Current Medical Research and Opinion Volume 24, 2008 - Issue 3
Submit an article Journal homepage
461
Views
21
CrossRef citations to date
0
Altmetric
Original Article

A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay

Jeff Schein Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ, USACorrespondence[email protected]
,
Carmela Janagap-Benson Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ, USA
,
Richard Grant Department of Medicine, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA
,
Vanja Sikirica Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ, USA
,
Dilesh Doshi Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ, USA
&
William Olson Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ, USA
Pages 895-906 | Accepted 15 Jan 2008, Published online: 14 Feb 2008

Citations (21)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Christopher J Llop, Edward Tuttle, Glenn S Tillotson, Kerry LaPlante & Thomas M File$suffix/text()$suffix/text(). (2017) Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study. Hospital Practice 45:1, pages 1-8.
Read now
Antoni Torres & Adamantia Liapikou. (2012) Levofloxacin for the treatment of respiratory tract infections. Expert Opinion on Pharmacotherapy 13:8, pages 1203-1212.
Read now
James E. Signorovitch, Mei Sheng Duh, Anirban Sengupta, Anna Gu, Richard Grant, Monika Raut, Samir H. Mody, Jeff Schein, Alan C. Fisher & Daniel Ng. (2010) Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin. Current Medical Research and Opinion 26:2, pages 355-363.
Read now
M. Raut, J. Schein, S. Mody, R. Grant, C. Benson & W. Olson. (2009) Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US. Current Medical Research and Opinion 25:9, pages 2151-2157.
Read now
C. R. Frei, T. C. Jaso, E. M. Mortensen, M. I. Restrepo, M. K. Raut, C. U. Oramasionwu, A. D. Ruiz, B. R. Makos, J. L. Ruiz, R. T. Attridge, S. H. Mody, A. Fisher & J. R. Schein. (2009) Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: A US-based study. Current Medical Research and Opinion 25:4, pages 859-868.
Read now

Articles from other publishers (16)

Guoying Cao, Yongjun Zhu, Xin Xie, Yuancheng Chen, Jicheng Yu, Jing Zhang, Zhiming Chen, Liewen Pang, Yingyuan Zhang & Yaoguo Shi. (2020) Pharmacokinetics and pharmacodynamics of levofloxacin in bronchial mucosa and lung tissue of patients undergoing pulmonary operation. Experimental and Therapeutic Medicine 20:1, pages 607-616.
Crossref
Mark Woodhead & Muhammad Noor. 2014. Community-Acquired Pneumonia. Community-Acquired Pneumonia 140 154 .
G. Cao, J. Zhang, X. Wu, J. Yu, Y. Chen, X. Ye, D. Zhu, Y. Zhang, B. Guo & Y. Shi. (2013) Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy C hinese volunteers and dosing regimen optimization . Journal of Clinical Pharmacy and Therapeutics 38:5, pages 394-400.
Crossref
Koichiro Otani, Brian Waterman & W. Claiborne Dunagan. (2012) Patient Satisfaction: How Patient Health Conditions Influence Their Satisfaction. Journal of Healthcare Management 57:4, pages 276-293.
Crossref
Timothy E. Albertson, Brian M. Morrissey & Andrew L. Chan. (2012) Are Fluoroquinolones Superior Antibiotics for the Treatment of Community-Acquired Pneumonia?. Current Infectious Disease Reports 14:3, pages 317-329.
Crossref
Ine Borghans, Rudolf B. Kool, Ronald J. Lagoe & Gert P. Westert. (2012) Fifty ways to reduce length of stay: An inventory of how hospital staff would reduce the length of stay in their hospital. Health Policy 104:3, pages 222-233.
Crossref
M. Woodhead, F. Blasi, S. Ewig, J. Garau, G. Huchon, M. Ieven, A. Ortqvist, T. Schaberg, A. Torres, G. van der Heijden, R. Read & T.J.M. Verheij. (2011) Guidelines for the management of adult lower respiratory tract infections - Full version. Clinical Microbiology and Infection 17, pages E1-E59.
Crossref
M. Woodhead, F. Blasi, S. Ewig, J. Garau, G. Huchon, M. Ieven, A. Ortqvist, T. Schaberg, A. Torres, G. van der Heijden, R. Read & T.J.M. Verheij. (2011) Guidelines for the management of adult lower respiratory tract infections - Summary. Clinical Microbiology and Infection 17, pages 1-24.
Crossref
Christopher R. Frei, Matthew J. Labreche & Russell T. Attridge. (2011) Fluoroquinolones in Community-Acquired Pneumonia. Drugs 71:6, pages 757-770.
Crossref
Marcos I. Restrepo & Christopher R. Frei. (2010) Health Economics of Use Fluoroquinolones to Treat Patients with Community-Acquired Pneumonia. The American Journal of Medicine 123:4, pages S39-S46.
Crossref
Howard Friedman, Xue Song, Simone Crespi & Prakash Navaratnam. (2009) Comparative Analysis of Length of Stay, Total Costs, and Treatment Success between Intravenous Moxifloxacin 400 mg and Levofloxacin 750 mg among Hospitalized Patients with Community-Acquired Pneumonia. Value in Health 12:8, pages 1135-1143.
Crossref
Xilong Pan, Hassan H. Dib, Minmin Zhu, Ying Zhang & Yang Fan. (2009) Absence of appropriate hospitalization cost control for patients with medical insurance: a comparative analysis study. Health Economics 18:10, pages 1146-1162.
Crossref
Sergio Carbonara, Laura Monno, Benedetta Longo & Gioacchino Angarano. (2009) Community-acquired pneumonia. Current Opinion in Pulmonary Medicine 15:3, pages 261-273.
Crossref
Robert C. Read, Javier Garau & Antoni Torres. (2008) Reply to Mohapatra et al.. Clinical Infectious Diseases 47:6, pages 857-858.
Crossref
Prasanta Raghab Mohapatra, Monica Gupta & Ashok K. Janmeja. (2008) Moxifloxacin Monotherapy in Severe Pneumonia: Do We Really Need It?. Clinical Infectious Diseases 47:6, pages 856-857.
Crossref
. (2013) Levofloxacin reduces LOS and costs in CAP. PharmacoEconomics & Outcomes News 549:1, pages 5-5.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.